Proteasome Treatment may Increase Risk of Cardiovascular Problems

Proteasome Treatment may Increase Risk of Cardiovascular Problems

New study carried out by Abramson Cancer Center of the University of Pennsylvania reports that carfilzomib drug can elevate risk of cardiovascular problems in patients suffering from multiple myeloma.

Findings of the study was published in JAMA Oncology journal in December 28, 2017. The proteasome inhibitor drug carfilzomib is used for treatment of multiple myeloma. Analysis of study shows that 18% of multiple myeloma patients receiving carfilzomib experienced cardiovascular adverse events (CVAE) such as hypertension, heart failure, heart attacks or arrhythmia.

More than eight percent of patients experience severe CVAEs more than twice as common as with other drugs for treating relapsed myeloma. According to estimates of American Cancer Society more than 30,200 people were suffering from MM in 2017. Standard treatments for treatment of these include chemotherapy and radiation and status of the patient can be improved with the use of proteasome inhibitors. FDA approved Carfilzomib as proteasome inhibitors, which has functions in breaking down and eliminate proteins inside a cell.

MM requires more proteasomes for survival of patients. The inhibitor drugs block the cells causing the cells to fill up with protein and die. “Like any cancer therapy, the concern with this approach is that it may have an effect on an otherwise healthy part of the body – in this case, the heart,” said the study’s lead author Adam J. Waxman, MD, a Hematology Oncology fellow in the Perelman School of Medicine at the University of Pennsylvania.

Results of the study found that 18.1% of patients taking carfilzomib experienced CVAE, with 8.2% of those cases being grade three or higher. For comparison, a similar review of bortezomib, another proteasome inhibitor found just 3.8% of patients experienced CVAE and only 2.3 percent were severe.

You may be interested

Herbal Tea Market, By Product Type, Flavor, and Distribution Channel
Healthcare
Healthcare

Herbal Tea Market, By Product Type, Flavor, and Distribution Channel

Sayali Tribhuvan - February 22, 2018

Herbal tea is derived from dried leaves, nuts, barks, seeds, grasses, fruits, flowers, and roots of various plants. There are several kind of tisanes or herbal teas…

Diabetes Monitoring Devices Market – Global Industry Analysis 2025
Healthcare
Healthcare

Diabetes Monitoring Devices Market – Global Industry Analysis 2025

Albert R - February 22, 2018

Diabetes monitoring devices refers to logging and measuring blood glucose levels, examining the data, and sharing it with health care providers to manage the disease. There are…

Orsted Collaborated with Oxford University to Optimize Offshore Wind Turbines Performance
Business
Business

Orsted Collaborated with Oxford University to Optimize Offshore Wind Turbines Performance

Alex Mathew - February 22, 2018

Denmark-based renewable power company, Orsted signed a five-year research agreement with the University of Oxford, U.K to optimize the design of foundation structures used for offshore turbines. Orsted…

Most from this category